Valeant Pharmaceuticals Intl Inc (VRX) Stock Rating Reaffirmed by Scotiabank

Vickie Mathis
January 13, 2017

To view the price target ranked by analysts, VRX attains high-level price target of 55 while lower level target was 9, it can be use an indication to know how much worth stock has stored in it.

Based on the finance research report, Equity analysts at the Brokerage firm Piper Jaffray reiterated their rating on Valeant Pharmaceuticals International, Inc. Deutsche Bank AG's price target points to a potential upside of 33.33% from the company's current price. MD raised its stake in Valeant Pharmaceuticals International by 16.1% in the third quarter. RBC Capital Markets reaffirmed a sector perform rating and issued a $46.00 price target on shares of Valeant Pharmaceuticals International in a report on Monday, September 26th.

Wall Street sell-side research analysts covering Valeant Pharmaceuticals International, Inc. Wells Fargo & Co. restated a "sell" rating and set a $19.50 price objective on shares of Valeant Pharmaceuticals International in a research note on Sunday, July 17th. Out of 23 Wall Street analysts rating Valeant Pharmaceuticals Intl, 7 give it "Buy", 3 "Sell" rating, while 13 recommend "Hold". The company presently has a consensus rating of "Hold" and an average target price of $34.80.

Shares of Valeant Pharmaceuticals International (NYSE:VRX) traded up 2.0215% on Wednesday, reaching $15.6399. They give the company shares an ABR of 3.14. Valeant Pharmaceuticals International has a one year low of $13.77 and a one year high of $119.87. The company's 50-day moving average is $15.15 and its 200 day moving average is $21.69. The company has a market cap of $5,330 million and there are 347,669,860 shares in outstanding. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 35.91% since June 8, 2016 and is downtrending. The specialty pharmaceutical company reported $1.55 EPS for the quarter, missing the consensus estimate of $1.78 by $0.23.

Investors will mark their calendars for 2017-03-21, the date when Valeant Pharmaceuticals International, Inc. While for the next 5 years, the growth estimate is 11.07%. VRX's profit will be $429.65M for 2.94 P/E if the $1.34 EPS becomes a reality. On average, equities research analysts expect that Valeant Pharmaceuticals International will post $5.63 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another domain, it was illegally stolen and republished in violation of United States & global copyright and trademark laws. Also, Director Thomas W. Sr. 19,185,570 shares of the stock were exchanged. 3 Insider Sales transactions were made totaling 4328940 shares traded. Following the acquisition, the director now owns 26,822 shares of the company's stock, valued at approximately $395,088.06.

Yesterday December short interest of the stock was released by FINRA. The remaining shorts are 8.8% of the total floated shares. The disclosure for this sale can be found here.

Valeant Pharmaceuticals International Inc (NYSE:VRX) institutional sentiment increased to 0.88 in Q3 2016.

Plane and train maker Bombardier Inc advanced 4.1 percent to C$2.57 after a consortium in which it has a 30 percent stake won a 1.16 billion euro contract to supply commuter trains for the Paris region. Seven Bridges Advisors LLC now owns 41,393 shares of the specialty pharmaceutical company's stock valued at $833,000 after buying an additional 890 shares during the period. Inc. bought a new stake in Valeant Pharmaceuticals International during the third quarter valued at $367,000. The firm now has a "hold" rating on the specialty pharmaceutical company's stock. Finally, Chartwell Investment Partners LLC bought a new stake in Valeant Pharmaceuticals International during the third quarter valued at $5,362,000.

Zacks provides the average brokerage recommendation (ABR) for thousands of stocks for institutions and retail investors alike. Valeant Pharmaceuticals International, Inc.is headquartered in Mississauga, Canada. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries.

Other reports by MyHealthBowl

Discuss This Article

FOLLOW OUR NEWSPAPER